Highly potent and selective activator of isozymes CA-VA and CA-VII

Novel Oral and Selective Prostaglandin F 2α (PGF 2α ) Receptor Antagonist

Novel PP1-targeting Ebola Virus (EBOV) inhibitor with improved pharmacological properties

Novel dose-dependent inhibitor of HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9, inhibiting Pseudomonas aeruginosa alginate synthesis

Novel EBV activator, well-performing EBV lytic cycle inducer

Novel potent specific inhibitor of EcDsbB, targeting disulfide bond forming enzyme

Novel specific inhibitor of EcDsbB, targeting disulfide bond forming enzyme DsbB of Gram-negative bacteria

Novel marine-derived anticancer saponin, targeting topoisomerase2alpha by unique interference with its DNA binding and catalytic cycle

Lipo-pro-prostaglandin E1, preventing hearing disturbance and equilibrium dysfunction due to inner ear microcirculatory disorders

An impurity of Edoxaban, a novel inhibitor of factor Xa

Novel eEF2K inhibitor, inducing significant apoptosis through classical apoptotic pathways

Potent agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma) with potential antineoplastic activity

Calcium channel blocker, blocking both T-type and L-type calcium channels

Natural alpha-aminobutyric acid-rich secondary metabolite of fungi, strongly inhibiting the BBMV V-ATPase, acting as a mitochondrial complex V inhibitor, showing antitumor activity in vivo

Antibiotic, inhibiting bacterial protein synthesis

Novel third-generation EGFR tyrosine kinase inhibitor, targeting EGFR T790M mutation in advanced non-small cell lung cancer

Novel EGFR inhibitor, attenuating Ang II-induced Kidney Fibrosis

Novel EGFR inhibitor, significantly reducing myocardial inflammation, fibrosis, apoptosis, and dysfunction, showing promises to the treatment on obesity-induced cardiac complications

Novel EGFR inhibitor, attenuating Ang II-induced Kidney Fibrosis

Potent inhibitor of adrenergic alpha1, alpha2c, 5-HT2a, 5HT7 receptors; Relatively selective blocker of adrenergic alpha2c over adrenergic alpha2a receptors.

Selective, non-competitive AMPA receptor antagonist, improving motor co-ordination

Antibacterial agent